Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 15, 2003. The report serves as a notification of changes in director interests regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific shareholding changes within an employee retirement plan.
Material Changes
The primary material change reported is an increase in the number of Ordinary Share American Depositary Receipts (ADRs) held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: April 11, 2003
- Previous Holding: 18,523,131 ADRs
- New Holding: 18,597,880 ADRs
- Average Price: $38.09
Management Commentary and Risks
The filing notes that the Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Consequently, Director Dr. J P Garnier is potentially interested in the shares held in the fund in the same manner as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of April 11, 2003 (18,597,880).
- Confirm the potential interest of Director Dr. J P Garnier in the fund's holdings.
- Note that this filing does not contain financial performance data for the period.